Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice

163Citations
Citations of this article
348Readers
Mendeley users who have this article in their library.
Get full text

Abstract

DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439–446, 2016. © 2016 Wiley Periodicals, Inc.

Cite

CITATION STYLE

APA

Zhu, H., Aryal, D. K., Olsen, R. H. J., Urban, D. J., Swearingen, A., Forbes, S., … Hochgeschwender, U. (2016). Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice. Genesis, 54(8), 439–446. https://doi.org/10.1002/dvg.22949

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free